Category

News
This article was originally published by Cancer Therapy Advisor Researchers have used deep whole-genome sequencing (WGS) to identify genomic markers of a “good-risk” group of patients with multiple myeloma with prolonged survival. Specifically, patients found to have a low genomic scar score and chromosome 9 gain had superior outcomes. In the study, researchers analyzed WGS...
Continue Reading
This was originally published by AJMC Severe renal impairment (RI) is associated with decreased rates of survival among patients with multiple myeloma (MM), even if renal function is restored with therapy, according to new research. Investigators from Fujian Medical University Union Hospital in China found patients who achieved restoration of renal function recovery had somewhat better odds...
Continue Reading
This article was originally published by Cancer Therapy Advisor Receipt of dialysis may be a risk factor for inpatient mortality in patients with multiple myeloma (MM) being treated with high-dose melphalan and autologous stem cell transplantation (HDM-ASCT), according to study results published in the European Journal of Haematology. To evaluate inpatient mortality trends, investigators conducted a...
Continue Reading
This post was originally published by Myeloma Research News GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approved in the European Union, by the Committee for Medicinal Products for Human Use (CHMP), for heavily treated multiple myeloma patients. The marketing authorization application, accepted for review in February, is specific for people with relapsed or refractory disease who were previously treated with an immunomodulatory agent, a proteasome inhibitor, and...
Continue Reading
An office of the U.S. Food and Drug Administration (FDA has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, be approved for heavily pretreated relapsed or refractory multiple myeloma patients. The recommendation by the FDA’s  Oncologic Drugs Advisory Committee is for patients who had at least four prior lines of treatment, including an immunomodulatory agent, a proteasome inhibitor,...
Continue Reading
Come along to our Whangarei Myeloma Patient Seminar, hosted by Myeloma New Zealand and Leukaemia & Blood cancer New Zealand. During the evening, we will hear from Ken Romeril (Myeloma NZ) and Dr Sarah Poplar (Northland DHB) who will discuss some of the changes to come in 2020 for Myeloma treatment. Wednesday 12 August5.30pm to...
Continue Reading
This post was originally published by Myasthenia Gravis News A 60-year-old man being treated for multiple myeloma was found to have myasthenia gravis (MG) caused by antibodies against muscle-specific tyrosine kinase (MuSK), a study reports. This unusual case indicates that cancer treatments may mask the symptoms of MG, complicating diagnosis, researchers said. The case was described in the journal BMC Neurology,...
Continue Reading
This was originally posted by Cision PR Newswire SALT LAKE CITY, July 9, 2020 /PRNewswire/ — HealthTree®, the first online portal for multiple myeloma cancer patients to find their best treatment options and help accelerate a cure, today announced the launch of HealthTree University (HTU), the first comprehensive resource that empowers multiple myeloma patients to become experts in...
Continue Reading
This article was originally published by Cancer Network Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on clinical hold following the submission of a patient’s safety report. The FDA placed the MELANI-01 trial on hold following the submission of a safety report, according to a Cellectis press release. The safety report...
Continue Reading
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple myeloma. Although stem cell mobilization is successful in the majority of patients with multiple myeloma, the use of granulocyte colony-stimulating factor (G-CSF) used alone is associated with up to a 10% failure rate, Kumar explains....
Continue Reading
1 2 3 24

Floor 7, 90 The Terrace
Wellington Central
New Zealand